We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-2.73%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$535M
AUM Growth
-$66.7M
Cap. Flow
+$12.3M
Cap. Flow %
2.29%
Top 10 Hldgs %
59.08%
Holding
57
New
9
Increased
13
Reduced
14
Closed
9
Avg Time Held
5.6 quarters
Top 10 Avg Time Held
4.9 quarters
Top 20 Avg Time Held
5 quarters

Top Buys

Rank Stock Value
1
SMLR icon
Semler Scientific
SMLR
+$28.5M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$4.22M
3
KROS icon
Keros Therapeutics
KROS
+$4.18M
4
FOLD icon
Amicus Therapeutics
FOLD
+$3.28M
5
CMRX icon
Chimerix, Inc.
CMRX
+$2.75M

Top Sells

Rank Stock Value
1
EPIX icon
ESSA Pharma
EPIX
+$8.12M
2
MCRB icon
Seres Therapeutics
MCRB
+$5.96M
3
WGS icon
GeneDx Holdings
WGS
+$5.24M
4
LUMO icon
Lumos Pharma, Inc. Common Stock
LUMO
+$3.82M
5
KZR icon
Kezar Life Sciences
KZR
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 99.64%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
OCUL icon
1
Ocular Therapeutix
OCUL
$1.66B
$64.8M 12.1%
6,480,000
– –
2019 Q1
10 quarters
CLDX icon
2
Celldex Therapeutics
CLDX
$2.24B
$53M 9.91%
985,000
– –
2020 Q2
5 quarters
CDXS icon
3
Codexis
CDXS
$152M
$31.3M 5.84%
1,345,000
– –
2014 Q1
30 quarters
CMRX icon
4
DELISTED
Chimerix, Inc.
CMRX
$31.1M 5.82%
5,030,000
+400,000
+9% +$2.75M
2020 Q2
5 quarters
HROW icon
5
Harrow
HROW
$1.06B
$29.9M 5.58%
3,285,000
+145,000
+5% +$1.31M
2018 Q3
12 quarters
SMLR icon
6
DELISTED
Semler Scientific
SMLR
$28.2M 5.27%
+225,566
New +$28.5M
2021 Q3
0 quarters
BBIO icon
7
BridgeBio Pharma
BBIO
$12.5B
$24M 4.48%
511,500
-5,650
-1% -$303K
2021 Q1
2 quarters
CYTK icon
8
Cytokinetics
CYTK
$8.66B
$20.7M 3.87%
580,000
– –
2020 Q2
5 quarters
TARA icon
9
Protara Therapeutics
TARA
$160M
$17.7M 3.31%
2,558,472
– –
2019 Q3
8 quarters
ETON icon
10
Eton Pharmaceutcials
ETON
$1.57B
$15.6M 2.91%
3,088,100
-604,500
-16% -$3.14M
2018 Q4
11 quarters
KNSA icon
11
Kiniksa Pharmaceuticals
KNSA
$6.16B
$14.9M 2.79%
1,310,000
+154,800
+13% +$2.02M
2020 Q2
5 quarters
KROS icon
12
Keros Therapeutics
KROS
$225M
$13.9M 2.6%
352,500
+117,500
+50% +$4.18M
2021 Q1
2 quarters
STXS icon
13
Stereotaxis
STXS
$109M
$13.6M 2.54%
2,526,500
– –
2019 Q3
8 quarters
FBIO icon
14
Fortress Biotech
FBIO
$67.7M
$12.1M 2.26%
250,000
-8,333
-3% -$407K
2020 Q2
5 quarters
PRQR icon
15
ProQR Therapeutics
PRQR
$219M
$11.9M 2.23%
1,424,200
+43,800
+3% +$286K
2021 Q1
2 quarters
STRO icon
16
Sutro Biopharma
STRO
$194M
$10.2M 1.9%
53,780
+4,090
+8% +$778K
2020 Q3
4 quarters
TCON
17
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$9.75M 1.82%
125,919
– –
2020 Q3
4 quarters
MGNX icon
18
MacroGenics
MGNX
$225M
$9.67M 1.81%
462,000
-116,150
-20% -$2.8M
2019 Q4
7 quarters
LRMR icon
19
Larimar Therapeutics
LRMR
$242M
$9.6M 1.79%
832,807
+105,007
+14% +$1.26M
2021 Q2
1 quarter
PCVX icon
20
Vaxcyte
PCVX
$10.7B
$8.97M 1.67%
353,400
-4,400
-1% -$107K
2020 Q3
4 quarters
CRNX icon
21
DELISTED
Crinetics Pharmaceuticals
CRNX
$8.46M 1.58%
402,113
+201,613
+101% +$4.22M
2021 Q1
2 quarters
XOMA icon
22
DELISTED
Xoma
XOMA
$8.37M 1.56%
338,350
-5,250
-2% -$155K
2017 Q1
18 quarters
NGNE icon
23
Neurogene
NGNE
$463M
$7.57M 1.41%
52,365
-5,445
-9% -$834K
2019 Q3
8 quarters
ADMS
24
DELISTED
Adamas Pharmaceuticals
ADMS
$7.17M 1.34%
1,460,000
-210,600
-13% -$1.02M
2020 Q2
5 quarters
VSTM icon
25
Verastem
VSTM
$720M
$7.16M 1.34%
193,750
– –
2020 Q3
4 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2021 Portfolio in Review

As of Q3 2021, Opaleye Management held 57 positions worth $535M, down 11% from $602M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management's Q3 2021 filing shows 9 new, 13 increased, 14 reduced and 9 closed positions. Its largest new stake was Semler Scientific: 225,566 shares worth $28.2M. The largest sale was ESSA Pharma, an estimated $8.12M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Opaleye Management's largest Q3 2021 buy was Semler Scientific: 225,566 shares worth $28.2M.
  • Opaleye Management added most to Crinetics Pharmaceuticals in Q3 2021, an estimated $4.22M increase.
  • Opaleye Management's biggest Q3 2021 reduction was Eton Pharmaceutcials, cutting an estimated $3.14M.
  • Opaleye Management fully exited ESSA Pharma in Q3 2021, selling an estimated $8.12M.
  • Opaleye Management's ten largest holdings make up 59% of its $535M portfolio in Q3 2021.
  • Opaleye Management opened 9 new positions and closed 9 in Q3 2021.
  • Opaleye Management's portfolio value fell 11% quarter-over-quarter to $535M.

Based on Opaleye Management's 13F filing for Q3 2021, filed 16 Nov 2021.